Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $107.50 Consensus PT from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned an average recommendation of “Hold” from the twenty-two research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $107.50.

Several research analysts have issued reports on ZBH shares. UBS Group decreased their target price on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective for the company. BTIG Research lowered their price objective on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Baird R W lowered Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, Robert W. Baird restated a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Key Financial Inc raised its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. grew its holdings in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC increased its position in Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 149 shares during the last quarter. Root Financial Partners LLC bought a new position in Zimmer Biomet in the third quarter valued at about $31,000. Finally, Mather Group LLC. purchased a new position in Zimmer Biomet in the third quarter worth about $36,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 0.4%

Zimmer Biomet stock opened at $89.44 on Friday. Zimmer Biomet has a 12 month low of $85.33 and a 12 month high of $114.44. The company has a market capitalization of $17.73 billion, a price-to-earnings ratio of 22.14, a price-to-earnings-growth ratio of 2.36 and a beta of 0.61. The business’s fifty day simple moving average is $94.68 and its two-hundred day simple moving average is $96.67. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.Zimmer Biomet’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.